Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Petra Krhovska

Single Agent Daratumumab in Advanced Multiple Myeloma Possesses Significant Efficacy Even in an Unselected "Real-World" Population

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

English

Related publications

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology

Hematology

2019

English

Real World Data of the Impact of First Cycle Daratumumab on Multiple Myeloma and AL Amyloidosis Services

British Journal of Haematology

Hematology

2017

English

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

European Journal of Haematology

Medicine

Hematology

2007

English

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma

British Journal of Haematology

Hematology

2020

English

Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone

Internal Medicine

Medicine

2019

English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology

English

Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma

English

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology

English

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Petra Krhovska

Single Agent Daratumumab in Advanced Multiple Myeloma Possesses Significant Efficacy Even in an Unselected "Real-World" Population

Related publications

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Real World Data of the Impact of First Cycle Daratumumab on Multiple Myeloma and AL Amyloidosis Services

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma

Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses